TiumBio Co., Ltd. (KOSDAQ:321550)
South Korea · Delayed Price · Currency is KRW 4,370.00
+15.00 (0.34%)
At close: Sep 4, 2026
TiumBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 14,997 | 12,289 | 6,792 | 4,899 | 9,118 | 56.8 |
Other Revenue | -0 | -0 | -0 | - | - | - |
| 14,997 | 12,289 | 6,792 | 4,899 | 9,118 | 56.8 | |
Revenue Growth | 104.49% | 80.92% | 38.65% | -46.27% | 15952.75% | -94.58% |
Cost of Revenue | 9,074 | 7,244 | 4,844 | - | - | - |
Gross Profit | 5,923 | 5,044 | 1,948 | 4,899 | 9,118 | 56.8 |
Selling, General & Admin | 8,092 | 7,981 | 7,368 | 11,610 | 9,999 | 5,008 |
Research & Development | 10,516 | 9,669 | 9,481 | 17,867 | 21,287 | 25,801 |
Amortization of Goodwill & Intangibles | 134.11 | 141.84 | 344.51 | 529.2 | 526.84 | 469.03 |
Operating Expenses | 22,005 | 21,183 | 20,647 | 32,731 | 34,758 | 32,753 |
Operating Income | -16,082 | -16,139 | -18,699 | -27,832 | -25,640 | -32,696 |
Interest Expense | -5,120 | -5,452 | -4,044 | -2,471 | -808.36 | -518.46 |
Interest & Investment Income | 377.7 | 534.3 | 479.94 | 1,225 | 1,305 | 919.34 |
Earnings From Equity Investments | - | - | 11,171 | -1,257 | -1,303 | -385.86 |
Currency Exchange Gain (Loss) | 754.09 | 166.53 | 141.51 | 127.42 | 65.61 | -11.63 |
Other Non Operating Income (Expenses) | 74.11 | -109.64 | -8,762 | -2,337 | -3,991 | 612.57 |
EBT Excluding Unusual Items | -19,996 | -21,000 | -19,712 | -32,544 | -30,372 | -32,080 |
Gain (Loss) on Sale of Investments | 2,756 | 3,351 | -5,873 | 1,728 | -1,037 | -172.6 |
Gain (Loss) on Sale of Assets | -37.93 | -11.67 | -10.1 | -13.27 | 6.28 | -0 |
Other Unusual Items | -1,126 | -1,126 | 2,049 | 11,792 | - | - |
Pretax Income | -18,403 | -18,787 | -23,546 | -19,038 | -31,402 | -32,253 |
Earnings From Continuing Operations | -18,403 | -18,787 | -23,546 | -19,038 | -31,402 | -32,253 |
Minority Interest in Earnings | 1,292 | 1,426 | 2,903 | 1,127 | 1,550 | 615.61 |
Net Income | -17,111 | -17,360 | -20,644 | -17,911 | -29,853 | -31,637 |
Net Income to Common | -17,111 | -17,360 | -20,644 | -17,911 | -29,853 | -31,637 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 28 | 27 | 26 | 24 | 24 | 24 |
Shares Outstanding (Diluted) | 28 | 27 | 26 | 24 | 24 | 24 |
Shares Change | 7.45% | 4.93% | 5.92% | 1.79% | 0.63% | 1.39% |
EPS (Basic) | -600.80 | -640.37 | -799.00 | -734.27 | -1245.75 | -1328.50 |
EPS (Diluted) | -600.80 | -640.37 | -799.00 | -734.27 | -1246.00 | -1329.00 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -15,695 | -15,567 | -16,668 | -38,952 | -27,198 | -36,647 |
Free Cash Flow Per Share | -551.07 | -574.22 | -645.13 | -1596.88 | -1134.99 | -1538.88 |
Gross Margin | 39.49% | 41.05% | 28.68% | 100.00% | 100.00% | 100.00% |
Operating Margin | -107.23% | -131.33% | -275.30% | -568.14% | -281.22% | -57566.15% |
Profit Margin | -114.10% | -141.27% | -303.93% | -365.62% | -327.42% | -55701.69% |
Free Cash Flow Margin | -104.65% | -126.68% | -245.40% | -795.14% | -298.31% | -64522.48% |
EBITDA | -12,538 | -12,462 | -14,901 | -24,578 | -22,169 | -30,753 |
EBITDA Margin | -83.60% | -101.41% | -219.38% | - | -243.14% | - |
D&A For EBITDA | 3,544 | 3,677 | 3,799 | 3,254 | 3,472 | 1,944 |
EBIT | -16,082 | -16,139 | -18,699 | -27,832 | -25,640 | -32,696 |
EBIT Margin | -107.23% | -131.33% | -275.30% | - | -281.22% | - |